0000899243-20-025345.txt : 20200916
0000899243-20-025345.hdr.sgml : 20200916
20200916171755
ACCESSION NUMBER: 0000899243-20-025345
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200915
FILED AS OF DATE: 20200916
DATE AS OF CHANGE: 20200916
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dallas Jayson Donald Alexander
CENTRAL INDEX KEY: 0001650322
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37519
FILM NUMBER: 201179486
MAIL ADDRESS:
STREET 1: AIMMUNE THERAPEUTICS, INC.
STREET 2: 8000 MARINA BOULEVARD, SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc.
CENTRAL INDEX KEY: 0001631650
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452748244
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
BUSINESS PHONE: (650) 614-5220
MAIL ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
FORMER COMPANY:
FORMER CONFORMED NAME: Allergen Research Corp
DATE OF NAME CHANGE: 20150123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-15
0
0001631650
Aimmune Therapeutics, Inc.
AIMT
0001650322
Dallas Jayson Donald Alexander
AIMMUNE THERAPEUTICS, INC.
8000 MARINA BOULEVARD, SUITE 300
BRISBANE
CA
94005-1884
1
1
0
0
President and CEO
Common Stock, $0.0001 par value
2020-09-15
4
F
0
1642
34.25
D
117034
D
The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award.
Includes 33,000 restricted stock units ("RSUs") which will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Includes the balance of 35,000 RSUs which will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Includes the balance of 60,000 RSUs which will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from June 19, 2018 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
/s/ Douglas T. Sheehy, as Attorney-in-Fact for Jayson Donald Alexander Dallas
2020-09-16